Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Becky Sharp

Nurse Practitioner Rapid City, SD Nurse Practitioner

NPI 1568912996 CMS profile 11129933

353 Fairmont Blvd, Rapid City, SD 57701

Open in the dashboard

General payments

$4,413

74 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Becky Sharp of Rapid City, SD is reported in the CMS Open Payments database as having received $4,413 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,316 30
2024 General $523 21
2023 General $385 9
2022 General $717 8
2021 General $472 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Becky Sharp
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Becky Sharp were reported at $2,316. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Becky Sharp Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $472 $135 $40–$426 $132
2022 $717 $152 $48–$470 $149
2023 $385 $166 $54–$529 $160
2024 $523 $173 $55–$556 $164
2025 $2,316 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Edwards Lifesciences Corporation $2,254 19 payments
  2. Medtronic, Inc. $1,621 45 payments
  3. Abbott Laboratories $174 2 payments
  4. Alnylam Pharmaceuticals Inc. $125 1 payment
  5. Merck Sharp & Dohme Corporation $113 1 payment
  6. Boston Scientific Corporation $82 4 payments
  7. Novartis Pharmaceuticals Corporation $24 1 payment
  8. Jazz Pharmaceuticals Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,084 67 payments
  2. Travel and Lodging $1,328 6 payments
  3. Education $1 1 payment
Products named General payments · program years 2021–2025
  1. SAPIEN 3 Ultra RESILIA $1,303 15 payments
  2. COREVALVE EVOLUT R $1,283 41 payments
  3. CoreValve Evolut $199 2 payments
  4. IN.PACT AV $125 1 payment
  5. ONPATTRO $125 1 payment
  6. TRICLIP $121 1 payment
  7. WINREVAIR $113 1 payment
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $97 1 payment
  9. WATCHMAN FLX $82 4 payments
  10. MitraClip System $53 1 payment
  11. Other $79 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

637

Median for Nurse Practitioner: 389

Drug cost

$49,844

Median for Nurse Practitioner: $21,885

Branded share of claims

44.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 52 $35,929
Xarelto Rivaroxaban Brand 11 $9,379
Clopidogrel Clopidogrel Bisulfate Brand 223 $2,082
Metoprolol Succinate Generic 91 $1,041
Potassium Chloride Generic 34 $319
Losartan Potassium Generic 27 $252
Furosemide Generic 68 $215
Rosuvastatin Calcium Generic 13 $141
Atorvastatin Calcium Generic 16 $136
Carvedilol Generic 26 $115

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$10,085

Medicare's payments for the services billed

Medicare patients

139

Average age 80

Services billed

198

67 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Heart failure 60%
Arthritis 46%
Atrial fibrillation 42%
Diabetes 40%
Chronic kidney disease 35%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record